Black Rock Inc. Acurx Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 27,503 shares of ACXP stock, worth $22,552. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,503

Previous 18,688 47.17%

Holding current value

$22,552

Previous $45,000 35.56%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.64 - $2.79 $14,456 - $24,593	8,815 Added 47.17%	27,503 $61,000
Q1 2024 May 10, 2024	SELL	$1.94 - $4.81 $86,209 - $213,746	-44,438 Reduced 70.4%	18,688 $45,000
Q4 2023 Feb 13, 2024	BUY	$1.28 - $5.76 $57,600 - $259,200	45,000 Added 248.26%	63,126 $241,000
Q3 2023 Nov 13, 2023	SELL	$1.41 - $2.55 $1,056 - $1,909	-749 Reduced 3.97%	18,126 $27,000
Q2 2023 Aug 11, 2023	BUY	$2.47 - $3.53 $6,703 - $9,580	2,714 Added 16.79%	18,875 $50,000
Q1 2023 May 12, 2023	BUY	$3.06 - $4.5 $1,597 - $2,349	522 Added 3.34%	16,161 $55,000
Q4 2022 Feb 13, 2023	BUY	$2.75 - $4.1 $247 - $368	90 Added 0.58%	15,639 $62,000
Q3 2022 Nov 14, 2022	SELL	$3.0 - $4.78 $1,305 - $2,079	-435 Reduced 2.72%	15,549 $47,000
Q2 2022 Aug 12, 2022	SELL	$2.42 - $4.0 $1,730 - $2,860	-715 Reduced 4.28%	15,984 $61,000
Q1 2022 May 12, 2022	BUY	$3.11 - $4.74 $31,143 - $47,466	10,014 Added 149.8%	16,699 $55,000
Q4 2021 Feb 10, 2022	BUY	$4.02 - $5.64 $683 - $958	170 Added 2.61%	6,685 $29,000
Q3 2021 Nov 09, 2021	BUY	$3.77 - $6.18 $24,561 - $40,262	6,515 New	6,515 $33,000

Others Institutions Holding ACXP

# of Institutions

Shares Held

1.25M

Call Options Held

9.3K

Put Options Held

9.7K

View Full List

About Acurx Pharmaceuticals, Inc.

Ticker ACXP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,556,600
Market Cap $9.48M
Description
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...

More about ACXP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account